Pharmacy purchase price (PPP)

The pharmacy purchase price is the price a pharmacy pays the wholesaler for a pack, before the pharmacy margin and before VAT. It sits one stage below the retail price and one stage above the ex-factory price. Scandinavia regulates and publishes it, Germany publishes it alongside the manufacturer price under a licence, and most other European countries do not publish it at all.

Definition and position in the chain

Four stages matter, and the pharmacy purchase price is the third:

1. Ex-factory price, the manufacturer selling price to the wholesaler.
2. Wholesale purchase price, what the wholesaler actually pays after discounts. Published in none of the 30 European countries reviewed.
3. Pharmacy purchase price, what the pharmacy pays the wholesaler, often a regulated maximum.
4. Retail price, what the patient or payer pays, usually including VAT.

The distinction between stages two and three is the one that is most often lost. A regulated pharmacy purchase price is a maximum or reference figure set by a formula. It is not a record of a negotiated transaction.

National terms and where it is published

For the remaining countries the level has to be calculated, either upwards from a published ex-factory price or downwards from a published retail price.

How it is derived where it is not published

Upward from ex-factory, you add the statutory wholesale margin. Downward from retail, you remove VAT and the pharmacy margin. Both directions run through the national formula, and three details decide whether the result holds:

• Order of operations. Fixed amounts are removed first, then percentage rates. Applying them in the other order produces a systematic error on every pack that falls in a band with a fixed component.
• Caps. Germany caps the wholesale margin at 37.80 euro, and the cap applies from a manufacturer price of 1,200 euro upwards. Estonia caps both trade stages at 6.39 euro per pack.
• Band basis. A margin scale can be read against the purchase price or against the selling price. The reading is not a matter of taste: for Finland the selling price reading is continuous at all band edges, with a largest jump of 0.0032 euro, while the purchase price reading jumps by up to 12.73 euro.

Why the level is worth getting right

Three practical consequences follow from using the pharmacy purchase price correctly.

Cross-country comparisons. A Swedish AIP against a Polish manufacturer price differs by the wholesale margin before any real price difference is measured.

Reference pricing. National formulae specify the level they reference. Norway sets maximum prices as the average of the three lowest prices from nine countries, and the level in that calculation is defined by the regulation, not by whatever file is at hand.

Procurement. For a hospital pharmacy or a wholesaler, the published pharmacy purchase price is the ceiling of the negotiation, not its outcome. The actual purchase price is below it, and that difference is not in any public file.

A worked example: from a Finnish consumer price to the pharmacy purchase price

Finland publishes both a wholesale price through Hila and a consumer price through Kela, which makes it a useful illustration of the arithmetic.

Starting from the consumer price including tax, three steps lead down the chain:

1. Remove VAT at 13.5 percent. The rate applies since 1 January 2026 and the authority file names it directly. It was recalculated against 5,945 rows.
2. Remove the pharmacy scale. Six bands, each with a factor and a fixed component, read against the selling price.
3. Remove the distributor margin of 3 percent to reach the manufacturer level.

Stop after step two and you have the pharmacy purchase price. Continue through step three and you have the ex-factory level. The same file therefore yields two different, equally valid prices, and a dataset that does not say which one it carries is unusable for comparison.

What the level does not tell you

A published pharmacy purchase price answers what a pharmacy may be charged at most. It does not answer three questions that buyers usually care about:

• What was actually paid. Discounts below the regulated maximum are not published in any of the 30 countries reviewed.
• Whether the pack was available. Price files and shortage registers are separate sources with separate update rhythms.
• Whether the price is current. Update frequency ranges from daily in Sweden to every two weeks in Germany and Denmark, and the effective date is a property of the file, not of the price.

Conclusion

The pharmacy purchase price is published in seven of the 30 European countries reviewed, two of them only under a licence contract. Everywhere else it is a calculated figure whose quality depends on the statutory margin rule, the order in which fixed and percentage components are applied, and the correct reading of the band basis. Treat it as a regulated maximum, never as evidence of what was actually paid.

Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works.